Marco Meglio

At 12 months, patients with congestive heart failure and/or left atrial enlargement had an atrial fibrillation detection rate of 23.4% vs 5.0% for patients with neither attribute.

Six months after hospital discharge, COVD-19 headache was more frequently observed in those infected with the Delta variant vs Wuhan or Alpha variants.

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.

The newly announced prospective, randomized, placebo- and sham-controlled study, will include 150 patients, ages 18 to 55 years, with documented patent foramen ovale and a history of more than 1 migraine headache day per week.

Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.

Zilucoplan, a complement C5 inhibitor, demonstrated a safe and tolerable profile, while meeting its primary and secondary end points in the phase 3 RAISE trial—the basis for its new drug application.

The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.

The 26-patient trial includes 10 individuals with early-manifest Huntington disease on low-dose AMT-130 and 16 in the high-dose cohort, which will continue enrollment after a DSMB found no further safety concerns.

IPX203, an oral formulation of carbidopa/levodopa, the standard treatment for Parkinson disease, demonstrated statistically significant results in improving ON time relative to immediate release CD/LD.

The Child Neurology Foundation is using community outreach and a new social services network to help children with neurological conditions feel included in contemporary society.

More than half of the cohort achieved no evidence of disease activity and few patients showed disability progression after 48 weeks of treatment with ocrelizumab.

NurOwn, otherwise known as autologous mesenchymal stromal cells secreting neurotrophic factors cells, has demonstrated significant effects on disease progression in less severe forms of ALS.

After removing participants at higher risk of reaching a floor effect of the ALSFRS-R, those treated with NurOwn demonstrated a higher rate of clinical response and less function lost across 28 weeks than placebo.

The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on several analyses from the N-MOmentum trial that highlight the clinical use of biomarkers in NMO and NMOSD.

In a planned superiority analysis, the between-group difference of the 12-month change in MDS-UPDRS part III score was not statistically significant.

SCI-110 not only met its primary safety end points, but the agent showed benefits on secondary outcomes such as need to use rescue medication and exploratory outcomes such as appetite.

By leveraging digital technologies, the single-arm ARTIOS study will provide unique and comprehensive data that may enrich treatment outcomes for patients with relapsing multiple sclerosis.

Those who reported higher ALSFRS-R speech scores at baseline had significantly higher diadochokinetic and word rate than those who reported speech disturbances, or lower scores.

By comparing results with pooled placebo groups from the PRO-ACT database, the data showed a 67% slower ALSFRS-R progression with IPL344.

On King’s staging systems, ALSAQ-5 scores increased from 24.6 at stage 1 to 62.1 at stage 4, whereas for Milano-Torino Staging systems, patients’ ALSAQ-5 scores increased from 43.2 at stage 0 to 80.7 at stage 3.

Nearly one-fourth of the observed treatment-emergent adverse events were related to edaravone. Additionally, there were no serious TEAEs found, and TEAEs were mostly representative of ALS progression.

Treatment with RNS60 resulted in significantly slower rate of decline in FVC and eating and drinking domains of the ALSAQ-40 scale over a 24-week period.

Treatment with tegoprubart resulted in significant reductions of CD40L and CXCL13 levels that occurred after first infusion and sustained throughout the treatment period.

Once thought nearly impossible to treat, ALS has seen another step of progress with the approval of AMX0035 and a future of potential therapeutics on the way.

SBT-272, an investigational small molecule in development for ALS and other neurological disease of mitochondrial dysfunction, resulted in improved membrane potential and axonal outgrowth of TDP-43 in vitro.

The adult neurologist at Allegheny Health Network provided perspective on why there’s never been a better time to treat patients with myasthenia gravis.

Laurits Taul Madsen, a PhD candidate at Aarhus University, discussed the use of lower extremity function assessments to characterize patients with MS at risk for future falls.

In the meta-analysis, the Paleolithic and Mediterranean diets continued to outperform other dietary interventions such as ketogenic, anti-inflammatory, fasting, and calorie restriction on fatigue and quality-of-life outcomes.

Patients treated with PC-rTMS showed almost no decline in the CDR-SB score, and presented a clear advantage in terms of cognitive functions in contrast to the worsening of the score observed in the sham group.

Among those on early highly-effective treatments, shorter disease duration and shorter time between first treatment and current treatment led to more patients achieving no evidence of disease activity.